Low body weight and body mass index may be associated with musculoskeletal pain following imatinib discontinuation in chronic myeloid leukemia-Reference-Cited by-同舟云学术

Low body weight and body mass index may be associated with musculoskeletal pain following imatinib discontinuation in chronic myeloid leukemia

Published:2017 Issue: Volume:7 Page:33-35
ISSN:2213-0489
Container-title:Leukemia Research Reports
language:en
Short-container-title:Leukemia Research Reports

Author:

Katagiri Seiichiro,Tauchi Tetsuzo,Ando Keiko,Okabe Seiichi,Gotoh Moritaka,Ohyashiki Kazuma

Funder

Tokyo Medical University

Publisher

Elsevier BV

Subject

Oncology,Hematology

Reference10 articles.

1. How I determine if and when to recommend stopping tyrosine kinase inhibitor treatment for chronic myeloid leukaemia;Ross;Br. J. Haematol.,2014

2. Musculoskeletal pain in patients with chronic myeloid leukemia after discontinuation of imatinib: a tyrosine kinase inhibitor withdrawal syndrome?;Richter;J. Clin. Oncol.,2014

3. Age and dPCR can predict relapse in CML patients who discontinued imatinib: the ISAV study;Mori;Am. J. Hematol.,2015

4. Imatinib withdrawal syndrome and longer duration of imatinib have a close association with a lower molecular relapse after treatment discontinuation: the KID study;Lee;Haematologica,2016

5. Musculoskeletal pain after stopping tyrosine kinase inhibitor in patients with chronic myeloid leukemia: a questionnaire survey;Katagiri;Rinsho Ketsueki,2016

Cited by 9 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Chronic Myeloid Leukemia, from Pathophysiology to Treatment-Free Remission: A Narrative Literature Review;Journal of Blood Medicine;2023-04

2. Calcific tendinopathy: an unexpected side effect of tyrosine kinase inhibitor?;Leukemia & Lymphoma;2022-09-02

3. Withdrawal syndrome after tyrosine kinase inhibitors discontinuation in patients with chronic myeloid leukemia;Terapevticheskii arkhiv;2022-08-12

4. Tyrosine kinase inhibitor discontinuation in the management of chronic myeloid leukemia: a critical review of the current practice;Expert Review of Hematology;2020-12-01

5. Withdrawal Syndrome After Tyrosine Kinase Inhibitor Discontinuation in Patients With Chronic Myeloid Leukemia in the Russian Prospective Study RU-SKI;Clinical Lymphoma Myeloma and Leukemia;2020-05